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Background: Bacteria within a biofilm are phenotypically more resistant to antibiotics, desiccation, and the host
immune system, making it an important virulence factor for many microbes. Cranberry juice has long been used to
prevent infections of the urinary tract, which are often related to biofilm formation. Recent studies have found that
the A-type proanthocyanidins from cranberries have anti-biofilm properties against Escherichia coli.
Methods: Using crystal violet biofilm staining, resazurin metabolism assays, and confocal imaging, we examined
the ability of A-type proanthocyanidins (PACs) to disrupt the biofilm formation of Pseudomonas aeruginosa. We used
mass spectrometry to analyze the proteomic effects of PAC treatment. We also performed synergy assays and in vitro
and in vivo infections to determine whether PACs, alone and in combination with gentamicin, could contribute to the
killing of P. aeruginosa and the survival of cell lines and G. mellonella.
Results: Cranberry PACs reduced P. aeruginosa swarming motility. Cranberry PACs significantly disrupted the biofilm
formation of P. aeruginosa. Proteomics analysis revealed significantly different proteins expressed following PAC
treatment. In addition, we found that PACs potentiated the antibiotic activity of gentamicin in an in vivo model of
infection using G. mellonella.
Conclusions: Results suggest that A-type proanthocyanidins may be a useful therapeutic against the biofilm-mediated
infections caused by P. aeruginosa and should be further tested.
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Biofilms are colonies of bacteria encased within extracel-
lular polymeric matrix [1]. Sessile biofilm bacteria are
phenotypically different than planktonic bacteria, confer-
ring increased resistance to desiccation, antibiotics, and
the immune response. Antibiotics are able to kill the
planktonic cells released by the biofilm after its matur-
ation stages, but bacteria within the biofilm can persist,
causing chronic infections [2]. In biofilm formation, bac-
teria attach reversibly to a surface, and then begin to
produce extracellular polysaccharides. As the bacterial
number grows, quorum sensing allows a phenotypic
change in the bacteria. The biofilm matures and grows.* Correspondence: mvanhoek@gmu.edu
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unless otherwise stated.Eventually, proteins break down parts of the matrix so
that bacteria within the biofilm can disperse [2].
Cranberry juice has long been used to prevent infec-
tions of the urinary tract, which are often related to bio-
film formation [3-5]. Recent studies have found that the
A-type proanthocyanidins from cranberries have anti-
biofilm properties against Escherichia coli [6,7]. The pri-
mary active compound in cranberries is the condensed
tannin A-type proanthocyanidins (PACs), which com-
prises about 65% of cranberry non-dialyzable material
(NDM) [8]. This oligomer is comprised of several types
of alpha-linked flavan-3-ols that are substituted variously
with hydroxyls along the aromatic and fused oxytane
rings, as shown in Figure 1. It has been found that A-
type PACs are iron chelators, indicating that PACs may
disrupt normal bacterial function by limiting the supply
of iron [9]. PACs have been shown to prevent adhesion
and reduce biofilm production by a variety of pathogens
[10-14]. Research has revealed the ability of PACs tohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Structure of the A-type proanthocyanidin monomer.
This structure represents the published chemical structure of PAC,
the active ingredient in cranberry extract [8].
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in vitro and in vivo [15]. It has been shown that the
alpha linkages in the compounds seem to be necessary
to prevent adhesion [7]. Researchers have also found
that PACs impair flagellum-mediated motility by Pseudo-
monas aeruginosa [16]. Thus, cranberry contains a va-
riety of flavonols and proanthocyanidins that can be
isolated and assessed for antimicrobial and anti-virulence
activity [14,17-22].
P. aeruginosa is a Gram negative, opportunistic human
pathogen associated with colonization and infection of
vital organs such as the lungs, urinary tract, and kidneys
[23]. This is a serious issue for cystic fibrosis patients,
for whom P. aeruginosa colonization in the lung is the
leading cause of illness and death [24]. P. aeruginosa is
associated with many hospital-acquired infections due to
colonization of medical equipment. Infection is usually
associated with sepsis and general inflammation. This
bacterium is also implicated in the mixed biofilm infec-
tions of burn victims, chronic wounds and diabetic pres-
sure ulcers [25]. Biofilm formation is a major virulence
factor in P. aeruginosa, and treatments that address this
element of its pathogenicity are greatly needed.
In these experiments, we studied the ability of cran-
berry PACs to inhibit biofilm formation of P. aeruginosa,
potentiate the activity of gentamicin, as well as the abil-
ity of PACs to lessen Pseudomonas pathogenicity in vitro
and in vivo. The identification of natural products thatinhibit the biofilm formation of P. aeruginosa and other
important pathogens of humans is of great interest.
Methods
Bacteria and materials
P. aeruginosa ATCC 9027 was obtained from the American
Type Culture Collection (Manassas, VA). GFP-expressing
P. aeruginosa (Strain: PAO1-pTDK-GFP) was a generous
gift from Douglas Weibel from the University of Wisconsin
(Madison, WI). Both strains were grown overnight in
Tryptic Soy Broth (TSB, Difco 211825) in a shaking in-
cubator at 37°C, bacterial pellets frozen in 20% glycerol
at −80°C, and enumerated via serial dilution on Tryptic
Soy Agar (Difco 236950). Cranberry PACs were gener-
ously provided by A. Howell (Rutgers University, NJ)
and Ocean Spray.
Swarming motility assay
An assessment of the swarming motility of P. aeruginosa
strain PAO1 was performed as previously described with
minor modification [26]. TSB alone or with 100 μg/mL
PACs was inoculated with overnight grown bacterial
stocks. Overnight growth was adjusted with sterile 1X
PBS to OD600 0.6. Petri dishes were filled with about
15 mL of modified M9 medium with 0.5% granulated
agar (Difco 214530) and allowed to dry under laminar
flow for 60 min. 5 μL of bacterial inoculum was placed
in the center of the plate. Plates were incubated for 16 h at
30°C. Inhibition of swarming was measured qualitatively.
Biofilm production inhibition assay
Biofilm inhibition by cranberry PACs was measured by
the crystal violet stain method with some alterations
[27]. P. aeruginosa ATCC 9027 (105 CFU) in TSB was
incubated with varying concentrations of PACs, or with-
out treatment, in triplicate in a 96-well plate (Corning
353072) (24 h; 37°C). Initial turbidity was measured at
OD600. Wells were washed with tap water, and the bio-
film fixed at 60°C in a hybridization oven for 1 hour. The
plate was stained with 0.1% crystal violet for 5 minutes,
washed, and reconstituted with 33% acetic acid. The plate
was read on a spectrophotometer at OD590. Student’s
t-test was performed between the growth/biofilm ratio for
each experimental value and the negative control, as de-
termined by absorbance at OD600 and OD590.
Disruption of pre-formed biofilm
The disruption of pre-formed biofilm by cranberry PACs
was assayed using P. aeruginosa ATCC 9027 as previ-
ously described [25,28]. After biofilm formation (24 h,
37°C) in a 96-well plate (Corning, 353072), various con-
centrations of PACs were added to the wells in triplicate.
Wells without treatment served as the negative control.
After an additional incubation (24 h, 37°C), bacterial
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stain was performed as above in the biofilm production
inhibition assay.
Bacterial attachment assay
Attachment assays were performed in a 96-well microtiter
plate (Corning, 353072) as previously described [25,28].
Overnight cultures of P. aeruginosa ATCC 9027 were
grown in TSB to an OD600 of ~1.0. Bacterial culture was
added to wells containing varying concentrations of PACs,
or no PACs in triplicate. The plates were incubated (1 h,
37°C) to allow attachment and the absorbance was mea-
sured at OD600. The crystal violet stain was performed as
for the biofilm production assay [29].
MIC and checkerboard assays
The minimal inhibitory concentration of gentamicin for
P. aeruginosa ATCC 9027 was determined as previously
in Mueller Hinton Broth [30]. A checkerboard assay was
performed as previously described [31,32].
Confocal imaging of flow cell slides
The flow chamber was set up and inoculated as previ-
ously described, with some modifications [33]. Frozen
GFP+ P. aeruginosa (2 × 109 CFUs) was incubated for
1 h at 37°C in TSB and then was injected in a flow cell
unit (FC 284 Dual Channel Transmission Flow Cell, Bio-
Surface Technologies Corp.) with TSB and 100 μg/mL
ampicillin. PACs (10 μg in 1 mL) were injected simultan-
eously with the bacteria. Untreated GFP+ P. aeruginosa
was used as a control. Slides were imaged with a Nikon
TE-2000 confocal using Z-stack. Graphics generated
using Nikon EZ-C1 software. The experiment was per-
formed in duplicate.
Resazurin metabolism measurement assay
P. aeruginosa ATCC 9027 was grown in a 96-well plate
(Corning 353072) and treated with PACs in various con-
centrations, in the same manner as the biofilm produc-
tion inhibition assay. After 24 h growth, media was
aspirated, and wells washed with 1X PBS. Resazurin
(0.0064%) in TSB-C was added to each well. The OD590
was read kinetically in a spectrophotometer (30 min;
37°C). The quantitative difference in metabolic reduction of
resazurin was compared at the 15 min time point between
experimental and control wells with a Student’s t-test.
Calgary device
The Calgary device (Innovatech) HTP MBEC assay was
performed according to manufacturer’s instructions with
small changes. Bacteria (105 CFU/well) were exposed to
varying concentrations of PACs in TSB in the Calgary
device plate and incubated for 24 h at 37°C). Pegs on the
plate lid were washed twice in fresh 96-well plates withsterile PBS and sealed thoroughly on a third plate con-
taining PBS. This plate was sonicated for 30 min with
the sealed plate sitting on the surface of a water-bath
sonicator, and the resulting disrupted biofilm was plated
in triplicate via serial dilution on TSA plates. Experiment
was repeated 6 times. Experimental and control CFU
counts were compared via Student’s t-test.
Proteomic analysis
Treated and untreated P. aeruginosa was grown over-
night in TSB at 37°C in a shaking incubator, with or
without 100 μg/mL PACs. 1 mL was centrifuged to pel-
let (13,200 rpm, 10 min) and resuspended in 1 mL dis-
tilled water. Bacteria were lysed by repeated freeze-thaw
cycles. Protein content was measured by the BCA pro-
tein assay (Pierce) and samples adjusted to equivalent
protein concentrations with sterile water. 100 μg of pro-
tein were reduced by 10 mM dithiothreitol (DTT) for
30 minutes at 37°C, and then alkylated by 50 mM iodoa-
cetamide for 20 min at room temperature. The proteins
were digested by trypsin at 37°C for 6 h in a buffer con-
taining ammonium bicarbonate (50 mM, pH 9) and 2 M
urea. The digestion mixture was then acidified by adding
glacial acetic acid to a final concentration of 2% and
desalted by ZipTip (Millipore). The peptides were
analyzed by high sensitive LC-MS/MS using an LTQ-
Orbitrap mass spectrometer (Thermo Fisher) as previ-
ously described [34]. Tandem mass spectra collected by
Xcalibur (version 2.0.2) were searched against the NCBI
P. aeruginosa PAO1 protein database using SEQUEST
(Bioworks software from ThermoFisher, version 3.3.1)
with full tryptic cleavage constraints, static cysteine al-
kylation by iodoacetamide, and variable methionine oxi-
dation. Mass tolerance for precursor ions was 5 ppm
and mass tolerance for fragment ions was 0.25 Da. The
SEQUEST search results of proteomics data were filtered
by the criteria “Xcorr versus charge 1.9, 2.2, 3.0 for 1+,
2+, 3+ ions; ΔCn > 0.1; ranked top #1; probability of
randomized identification of peptide < 0.01”. Confident
peptide identifications were determined using these
stringent filter criteria for database match scoring
followed by manual evaluation of the results. The “false
discovery rate (FDR)” was estimated by searching a com-
bined forward-reversed database as described by Elias
[35]. The SEQUEST search results were exported to
spreadsheets and compared. Pathway classifications
were done manually using the Pseudomonas genomic
database (pseudomonas.org) and the KEGG Pathway
module.
Treatment of infected mammalian cells with PACs
J774A.1 mouse macrophage cells (ATCC TIB-67) and
HEK293T/17 human kidney epithelial cells (ATCC CRL-
11268) were acquired from the American Type Culture
Figure 2 Photographs of P. aeruginosa swarming motility on
modified M9 agar, with A. modified M9 agar and B. modified
M9 agar with 100 μg/mL cranberry PACs added.
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zen stock with limited passaging. Cells were grown in
Dulbecco’s Modified Eagle Medium (DMEM) with 10%
Fetal Bovine Serum (FBS) and 1% penicillin/strepto-
mycin. Cells were pelleted, washed once with PBS, pel-
leted again, and then resuspended in DMEM with 10%
FBS. A tissue culture-treated 96-well plate (Corning
353072) was seeded with 5 × 104 cells per well. P. aeru-
ginosa ATCC 9027 at a multiplicity of infection (MOI)
of 500 was added for 15 h. PACs (10 μg/mL) were added
to experimental wells simultaneously with the bacteria.
Non-infected cells were used to establish a spontaneous
LDH release control. LDH release was measured kinetic-
ally for 15–17.5 hours using a spectrophotometer at
OD490. The readings of treated wells were compared at
the 15 h time-point with control wells using a Student’s
t-test. Controls and experimental wells were set up in
triplicate and the assay was performed 3 times.
In vivo treatment of infected Galleria mellonella
(wax moth larvae)
G. mellonella larvae (waxworms) were purchased from
Vanderhorst Wholesale (St. Mary’s, OH) and used as a
model of bacterial infection as previously described [25].
All injections were done into the first proleg unless the
first proleg was deformed. The second injection was into
the second proleg if 2 injections were performed. The
waxworms weighed between 0.23-0.38 g. Tuberculin
needles (0.5 mL) were used for injections. The wax-
worms were stored in plastic petri dishes at 37°C after
injection and assessed for vital signs daily [25,30,36].
Statistical analysis
The means and the standard deviation were calculated
for the indicated experiments. The statistical analysis
performed was Student’s t-test with a level of signifi-
cance of p < 0.05.
Results and discussion
PACs reduced P. aeruginosa motility
A previous study found that cranberry PACs inhibited
the swarming motility of P. aeruginosa [16]. Our experi-
ments confirmed that the swarming motility of P. aeru-
ginosa was limited with the addition of 100 μg/mL PACs
(Figure 2). Untreated bacteria swarmed to the edge of the
agar plate (Figure 2A), while bacteria growing on PAC-
containing agar moved about half the distance (Figure 2B).
In addition, swarming patterns were not as branched or
complex.
Effect of cranberry PACs on P. aeruginosa biofilm
Previous studies of both Gram-positive and Gram-negative
bacteria have shown a significant decrease in biofilm
production when exposed to cranberry juice, cranberryextracts, and cranberry PACs [10-14]. In our experi-
ments, cranberry PACs significantly inhibited biofilm
formation of P. aeruginosa in vitro at concentrations as
low as 1 μg/mL (p < 0.05) (Figure 3A). At 1 μg/mL, PACs
inhibited biofilm formation 40.9%, while 10 μg/mL PACs
inhibited biofilm formation 55.7% (p < 0.01) compared to
the untreated P. aeruginosa.
When bacteria were allowed to attach and form biofilm
for 24 h before treatment, exposure to 10 μg/mL PACs for
an additional 24 h resulted in a 54.1% (p < 0.05) reduction
of preformed biofilm (compared to untreated control) and
at 100 μg/mL, a 39.6% at (p < 0.01) inhibition compared
to the untreated control (Figure 3B). PAC treatment
showed no significant effect on the attachment of P. aeru-
ginosa (Figure 3C). Using the Calgary device (consisting of
inverted plastic pegs that hang down into the media of a
96 well plate, to which bacteria attach and form biofilm),
exposure to PACs showed a 49.5% decrease in bacteria at-
tached to the inverted pegs as compared to control at
100 μg/mL (p < 0.1), but no statistical difference at any
other concentration (Figure 3D), confirming the pre-
formed biofilm results above.
In confocal imaging experiments in support of Figure 3A,
imaged after the incubation of bacteria with PACs in a flow
cell apparatus, it was found that biofilm height appeared to
decrease after PAC treatment. Figures 4A - D illustrate the
change in the height of P. aeruginosa biofilm, which de-
creased from ~26 μm to ~20 μm when treated with 10 μg
PACs during attachment phase. In addition, the biofilm
density also appeared to decrease.Proteomics of PAC-treated P. aeruginosa
To understand changes in global protein expression of
the bacterium in response to PACs treatment, P. aerugi-
nosa was grown overnight with or without PACs
(100 μg/mL), and then subjected to proteomic analysis
by mass-spectrometry (LC-MS-MS) (3 replicates). A
total of 1075 proteins were identified in the untreated
sample, and 1144 proteins were identified in treated
samples with 1% FDR (Figure 5A). The expression levels
of the identified proteins in the two samples were
Figure 3 Effects of cranberry PACs on P. aeruginosa. A. biofilm formation (PACs dissolved in DMSO), B. pre-formed biofilm (PACs dissolved in
deionized water), C. surface attachment, D. Bacterial number from treated and untreated biofilm using the Calgary device. * = p < 0.05; ** = p < 0.005;
*** = p < 0.001.
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tion method [34], and the result revealed many differen-
tially expressed proteins (Additional file 1: Table S1).
Of 159 proteins that had the largest differences in
abundance, the 30 most differentially regulated proteins
were chosen from each group (up- and down-regulated)
for examination in greater detail, as shown in Figure 5B.
The top 30 proteins are listed in Table 1 (up-regulated)
and Table 2 (down regulated). Proteins that were most
significantly up-regulated (Table 1) include 12 proteins
related to iron siderophores or cation transporters, for
example, PchD, PvdN, and PhuS. 5 proteins putatively
involved in amino acid synthesis were also up-regulated,
including PA0335, PA2044, and HutG. In addition, sev-
eral proteins that are up-regulated in response to stress
were also found, such as OsmC and SodM. A hypothet-
ical protein (PA3450) thought to be involved with fla-
vonoid metabolism was also up-regulated.
A wide variety of proteins were down-regulated due to
PACs treatment (Table 2). This included 2 proteins re-
lated to ATP synthesis, a likely cytochrome C (PA2482)
and hypothetical protein PA2481, and several proteins
involved in DNA and RNA synthesis, such as TopA,
RplC, and Mfd. In addition, several citric acid cycleproteins, such as subunits of the acetyl-CoA carboxylase
and fumarase, were found to be significantly reduced.
Though it was found that the presence of PACs inhibited
swarming motility, no proteins related to flagella or type
IV pili were found be down-regulated. The quorum-
sensing proteins in the las and rhl regulons were not found
to be differentially regulated when treated, except for
PvdQ, a quorum quencher [37], which had significantly
more peptide hits with PACs treatment. It has been sug-
gested that inhibition of quorum-sensing may be a mech-
anism to block P. aeruginosa biofilm production [37,38].
Further effect of cranberry PACs on biofilm-resident
P. aeruginosa
Metabolism in bacteria, as a measure of the number of
bacteria present, can be measured with the compound
resazurin, which becomes highly fluorescent when re-
duced to resorufin by chemicals or living cells, primarily
by NADH oxidoreductases in bacteria. Biofilm-resident
bacteria formed in the presence of higher concentrations
of cranberry PACs had lower metabolic rates than
biofilm-resident bacteria formed at lower concentrations
of PACs (Figure 6). P. aeruginosa treated with 100 μg/mL
PACs reduced 32.9% of the resazurin compared to the
Figure 4 Confocal imaging (3D Z stack and sections) of P. aeruginosa biofilm. A. Untreated: 3-dimensional Z stack after 24 h incubation
without PACs, B. Sections view after 24 h incubation without PACs, C. Treated: 3-dimensional Z stack after 24 h incubation with PACs, D. Sections
view after 24 incubation with PACs.
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10 μg/mL, PAC-treated P. aeruginosa biofilm reduced
36.9% of the untreated control (p < 0.01). Thus, these re-
sults most likely reflect a decrease in the total number of
bacteria remaining in the PACs-reduced biofilm. Several
citric acid cycle and ATP synthesis proteins were
down-regulated, so the effect of PACs-treatment on P.
aeruginosa biofilm may also be partly due to an effect
on bacterial metabolism.
In vitro potentiation of gentamicin by PACs
PAC is known to be an iron chelator [39], and some iron
chelators have been shown to potentiate the activity of an-
tibiotics, particularly aminoglycosides such as gentamicinand tobramycin [40]. To determine whether PACs may be
able to contribute to potentiation of the antibiotic activity
of gentamicin, a checkerboard assay was performed using
varying concentrations of PAC against various concentra-
tions of gentamicin. The PACs did not kill P. aeruginosa
at any concentration tested, and thus are not directly an-
timicrobial. Gentamicin had an MIC of 1.5 μg/mL
against this bacterial strain, which is in agreement with
published values [41]. However, the MIC of gentamicin
in combination with PACs was 1.3 μg/mL, as shown in
Table 3. Based on these results, we concluded that
PACs slightly potentiate the effect of the gentamicin
in vitro. Cranberry PACs may be considered as an adju-
vant to gentamicin.
Figure 5 A proteomics analysis of PAC treated P. aeruginosa. The general function of the top 30 up-regulated and top 30 down-regulated
proteins is illustrated, showing the general separation of function, and some overlapping functions between up- and down-regulated proteins.
Inset: The number of proteins identified in the untreated and treated samples. Total of 1075 proteins were identified in untreated sample, and
1144 proteins were identified in treated samples. Total of 1299 proteins were identified in the two samples, and total of 920 common proteins
were identified in both samples.
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HEK293T/17 cells with PACs
In order to determine if PACs treatment could rescue
eukaryotic cells during a P. aeruginosa infection, murine
macrophage cells (J774A.1) and human embryonic kid-
ney cells (HEK293T/17) were first treated with varying
concentrations of PACs, and then infected with P. aeru-
ginosa (MOI = 500) for 24 hours. The subsequent LDH
release assay measured the release of lactate dehydro-
genase, which is indicative of lysis. At 15 h, it was found
that 10 μg/mL PACs significantly rescued murine mac-
rophages from P. aeruginosa-mediated lysis, as shown by
reduced release of LDH compared to the untreated con-
trol (p < 0.05, Figure 7A). This concentration of PACs
also significantly rescued human embryonic kidney cells
from lysis by P. aeruginosa (p < 0.05, Figure 7B), with
full kinetic data from the experiment shown.
Treatment of P. aeruginosa-infected G. mellonella with
cranberry PACs in combination with gentamicin
Some potentiating effect was shown (Table 3) when gen-
tamicin was combined with PACs. To see if this effect
would occur in vivo, G. mellonella was infected with P.
aeruginosa and treated with sub-MIC concentrations of
gentamicin and low levels of PACs. G. mellonella wax-
worms are an in vivo infection model for multiplepathogens, including P. aeruginosa [25,30,36]. A Kaplan-
Meier survival analysis conducted on the results obtained
over a 72 h period (Figure 8) indicated that a combination
therapy of PACs and gentamicin was significantly (p < 0.05)
more effective in reducing larvae death as compared to
gentamicin treatment or PAC treatment alone. The ave-
rage ratio of death over the 72 h time course between
gentamicin alone, PAC alone, and gentamicin-PAC com-
bination treatment was 3.4:1, suggesting the significant sur-
vival benefit of having the combination treatment.Conclusions
PACs are phenolic oligomers found in relatively high
abundance within cranberries. Recent studies have found
that these polyphenol structures are effective in reducing
biofilm formation [42]. Cranberry juice and extracts have
historically been used to prevent urinary tract infections
in women [3-5]. The extracted NDM of cranberry has
been shown to prevent the formation of biofilm by S. epi-
dermis on soft contact lenses, which could reduce ocular
infections [43]. It has been shown previously that cran-
berry NDM contains primarily A-type PACs [43]. Cran-
berry NDM has been shown to interfere with quorum
sensing in Vibrio harveyi [44]. Cranberry NDM has also
been shown to reduce the colonization of Porphyromonas
Table 1 The top 30 up-regulated proteins in PAC-treated P. aeruginosa bacteria
Upregulated




fumarate hydratase FumC1 Central carbohydrate metabolism 15599666 0.1 21.3
ABC transporter ATP-binding protein PA4595 ABC-2 type or other transport systems 15599791 0.1 19
antioxidant protein PA3450 Phenylpropanoid and flavanoid biosynthesis 15598646 0.1 18
adhesion protein PA2407 Metallic cation, iron-siderophore and vitamin
B12 transport system
15597603 0.1 17
3-oxo-C12-homoserine lactone acylase PvdQ Metallic cation, iron-siderophore and vitamin
B12 transport system
15597581 0.1 16
pyochelin biosynthesis protein PchD Metallic cation, iron-siderophore and vitamin
B12 transport system
15599424 0.1 15.3
hypothetical protein PA2410 Metallic cation, iron-siderophore and vitamin
B12 transport system
15597606 0.1 13.3
hypothetical protein PA0335 Serine and threonine metabolism 15595532 0.1 12.3
protein PvdN Metallic cation, iron-siderophore and vitamin
B12 transport system
15597590 0.1 11.3
hypothetical protein PA4328 Stress protein 15599524 0.1 11
hypothetical protein PA3931 Metallic cation, iron-siderophore and vitamin
B12 transport system
15599126 0.1 10
hypothetical protein PA4657 ATP synthesis 15599852 0.1 9.7
osmotically inducible protein OsmC Stress protein 15595257 0.1 9
PmbA Replication system 15599668 0.1 8.3
sulfite reductase CysI Sulfur metabolism 15597035 0.1 7.3
superoxide dismutase SodM Stress protein 15599664 0.1 6.7
hypothetical protein PA3250 Metallic cation, iron-siderophore and vitamin
B12 transport system
15598446 0.1 6.7
hypothetical protein PA2699 Histidine metabolism 15597895 0.1 6.3
hypothetical protein PA2044 Cysteine and methionine metabolism 15597240 0.1 6.3
periplasmic polyamine binding protein PA0295 Mineral and organic ion transport system 15595492 0.1 6.3
heme/hemoglobin uptake outer membrane receptor PhuR Metallic cation, iron-siderophore and vitamin
B12 transport system
15599904 0.1 6
PhuS Metallic cation, iron-siderophore and vitamin
B12 transport system
15599903 0.1 5.7
pyocin S5 Pathogenicity 15596182 0.1 5.7
carbohydrate kinase PA3579 Lipid metabolism 15598775 0.1 5.3
hypothetical protein PA5229 Unknown function 15600422 0.1 5
heme uptake outer membrane receptor HasR Metallic cation, iron-siderophore and vitamin
B12 transport system
15598604 0.1 5
SpoVR family protein PA0586 Stress protein 15595783 0.1 5
hypothetical protein PA5359 Carbohydrate metabolism 15600552 0.1 4.7
N-formylglutamate amidohydrolase HutG Histidine metabolism 15600284 0.1 4.3
amidotransferase PauD2 Histidine metabolism 15596939 0.1 4.3
Ulrey et al. BMC Complementary and Alternative Medicine 2014, 14:499 Page 8 of 12
http://www.biomedcentral.com/1472-6882/14/499gingivalis and mixed biofilms of P. gingivalis and Fusobac-
terium nucleatum in periodontal sites [45,46].
In this study, we determined that cranberry PACs have
anti-biofilm activities against the gram-negative bacteriumP. aeruginosa. O’May and Tufenkji [47] showed that the
sessile biofilm lifestyle of P. aeruginosa is bolstered by the
presence of cranberry PACs, which limit motility, particu-
larly swarming motility. Our experiments confirmed that
Table 2 The top 30 down-regulated proteins in PAC treated P. aeruginosa bacteria
Downregulated





ABC transporter PA4502 Peptide/nickel export system 15599698 13.7 0
hypothetical protein PA2481 ATP synthesis 15597677 8 0
DNA topoisomerase I TopA Repair system 15598207 7.7 0
homogentisate 1,2-dioxygenase HmgA Aromatic amino acid metabolism 15597205 16.3 0.1
4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase
GcpE
Terpenoid backbone biosynthesis 15598998 11.3 0.1
inosine 5′-monophosphate dehydrogenase GuaB Purine metabolism 15598965 6.7 0.1
preprotein translocase subunit SecA Bacterial secretion system 15599599 6.7 0.1
hypothetical protein PA5545 Protein processing 15600738 6.7 0.1
adenosylmethionine-8-amino-7-oxononanoate
aminotransferase BioA
Cofactor and vitamin synthesis 15595617 6.3 0.1
hypothetical protein PA2765 Unknown function 15597961 6.3 0.1
3-ketoacyl-CoA thiolase FoaB Fatty acid metabolism 15598209 6 0.1
acetyl-CoA carboxylase subunit beta AccD Carbon fixation 15598308 5.7 0.1
30S ribosomal protein S3 RpsC Ribosome 15599453 5.7 0.1
ribonuclease E Rne RNA processing 15598172 5.3 0.1
bacterioferritin PA4880 Metallic cation, iron-siderophore and vitamin B12
xport system
15600073 5 0.1
50S ribosomal protein L13 RplM Ribosome 15599629 4.7 0.1
formate dehydrogenase subunit epsilon FdhE Other carbohydrate metabolism 15600003 4.7 0.1
hypothetical protein PA3967 Unknown function 15599162 4.3 0.1
lysine-specific pyridoxal 5′-phosphate-dependent
carboxylase LdcA
Arginine and proline metabolism 15597015 4 0.1
acetyl-CoA carboxylase subunit A PA5436 Citrate cycle 15600629 4 0.1
cytochrome C PA2482 ATP synthesis 15597678 3.3 0.1
threonine dehydratase IlvA1 Branched-chain amino acid metabolism 15595528 3 0.1
transcription-repair coupling factor Mfd Repair system 15598198 3 0.1
glycerate dehydrogenase HprA Photorespiration 15599822 3 0.1
hypothetical protein PA5201 Pathogenicity 15600394 3 0.1
fumarase PA4333 Citrate cycle 15599529 41.3 1.7
phosphopantetheine adenylyltransferase CoaD Cofactor and vitamin synthesis 15595560 14.3 0.7
aconitate hydratase PA0794 Citrate cycle 15595991 32.7 1.7
50S ribosomal protein L3 RplC Ribosome 15599459 10.7 0.7
formyltetrahydrofolate deformylase PurU1 Purine metabolism 15599510 4.7 0.3
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both in the distance moved and the complexity of the
swarming pattern.
We also found that PACs decreased biofilm produced
by P. aeruginosa when applied continuously to the cul-
ture, which is consistent with published results in other
Gram-negative bacteria such as E. coli and P. gingivalis
[10-14]. Our experiments with cranberry PACs demon-
strated a dose dependent reduction of preformed P. aer-
uginosa biofilm.Several groups have found that P-fimbriae-mediated
adherence to surfaces by E. coli is reduced by A-type
PACs [6,48]. Based on our attachment studies, PACs do
not significantly reduce the adherence of P. aeruginosa
to surfaces. P. aeruginosa attachment may not be af-
fected due to the fact that this organism contains no
P-fimbriae related attachment mechanisms. Planktonic
growth is reduced by high concentrations of PACs, and
PACs-treatment appears to reduce the total number of
P. aeruginosa within the biofilm.
Figure 6 Resazurin reduction of P. aeruginosa in biofilm
following cranberry PAC treatment. * = p < 0.05; ** = p < 0.005.
Figure 7 In vitro treatment of P. aeruginosa-infected mammalian
cells with cranberry PACs. A. J774A.1 mouse macrophage infected
cell line. B. HEk293T/17 human kidney epithelial cell line.▲ = untreated;
▼ = treated with PACs; ■ = no bacteria control.
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http://www.biomedcentral.com/1472-6882/14/499PACs have been shown to have an effect on a wide
variety of bacterial systems, as their primary mechanism
is iron chelation, an effect previously known in E. coli
[9]. Proteomic analysis in this study shows that PAC
treatment affects the abundance of many proteins in P.
aeruginosa. Several of the proteins that are less abundant
in the treated sample normally contain iron, such as
cytochromes, suggesting a potential role of PAC iron
chelation as a mechanism. Most notably, several of the
up-regulated proteins are iron siderophores. In addition,
Fe3+ is required for P. aeruginosa biofilms to fully ma-
ture into a large structure. It has been found that in
iron-limiting conditions, P. aeruginosa will only form
flat, thin biofilms [49], which we confirmed through
fluorescent microscopy. Bacteria in these thin biofilms
may be much less resistant to antibiotics and the host
immune system than bacteria in a fully developed bio-
film. Iron siderophores seem to be particularly effective
as potentiators of aminoglycosides against P. aeruginosa,
as it has been previously found that the activity of tobra-
mycin was augmented when used in conjunction with
lactoferrin [40].Table 3 Checkerboard assay of gentamicin and PACs
against P. aeruginosa, showing the decrease (potentiation)




1.7 1.6 1.5 1.4 1.3 1.2 1.1 0
100 0.081 0.084 0.079 0.088 0.178 0.698 0.841 1.74
10 0.066 0.066 0.069 0.067 0.093 0.439 0.693 1.746
1 0.057 0.055 0.054 0.059 0.07 0.461 1.137 1.743
0.1 0.108 0.056 0.053 0.06 0.056 0.903 1.687 1.774
0.01 0.056 0.054 0.063 0.053 0.062 1.002 1.197 1.794
0 0.054 0.061 0.055 0.241 0.647 1.267 1.727 1.806
Bold value indicates point of synergy.
Figure 8 PAC treatment of P. aeruginosa infection in G. mellonella.
Infected bacteria were exposed to PACs alone, gentamicin alone,
or gentamicin and PACs together. ○ = 1 μg/mL PACs only;
∇ = 104 CFU P. aeruginosa; ▼ = 104 CFU P. aeruginosa treated
w/ 0.5 μg/mL gentamicin; Δ = 104 CFU P. aeruginosa treated w/
1 μg/mL PACs; ● = 104 CFU P. aeruginosa treated w/ 0.5 μg/mL
gentamicin and 1 μg/mL PACs.
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http://www.biomedcentral.com/1472-6882/14/499We performed a series of experiments to explore how
PACs may affect the action of a traditional antibiotic
such as gentamicin. In vitro experiments showed the po-
tentiation effect of PACs on the MIC of gentamicin. This
was supported by in vivo studies in the G. mellonella
model which demonstrated that a low dose of gentami-
cin with PACs prolonged survival in P. aeruginosa-in-
fected worms significantly more than antibiotic or PACs
alone. Thus cranberry PACs may be acting as antibiotic
adjuvant for the action of gentamicin [50]. Cranberry
juice has long been used as a prophylactic for urinary
tract bacterial infection, and the use of PACs should be
further explored to potentiate the action of antibiotics
and reduce bacterial colonization and biofilm develop-
ment during other infections caused by P. aeruginosa.
Additional file
Additional file 1: Table S1. All up- and down-regulated proteins in
PAC treated P. aeruginosa bacteria as determined by LC/MS/MS.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RKU and SMB performed experiments, analyzed data, and contributed the
manuscript. WZ performed mass spectrometry, analyzed data, and
contributed to the manuscript. MVH conceived the study and contributed to
the manuscript. All authors approved the final manuscript.
Acknowledgments
We acknowledge A. Ahmed and R. Brandt for their role in early experiments on
this project and S. Dean for helpful discussions. We are grateful to A. Nwabueze
for assisting with the confocal microscopy and to Dr. A. Howell, Rutgers
University for providing PACS. Many thanks to J. Roman for assistance with cell
culture. RKU received an Undergraduate Research Apprenticeship from George
Mason University. SMB and MVH are supported by HDTRA1-12-C-0039 Translational
Peptide Research for Personnel Protection. Publication of this article is supported
by the George Mason University Open Access Fund.
Author details
1Department of Biology, George Mason University, Manassas, Virginia, USA.
2School of Systems Biology, George Mason University, Manassas, Virginia,
USA. 3Center for Applied Proteomics and Molecular Medicine, George Mason
University, Manassas, Virginia, USA. 4National Center for Biodefense and
Infectious Diseases, George Mason University, Manassas, Virginia, USA.
Received: 27 April 2014 Accepted: 11 December 2014
Published: 16 December 2014
References
1. Flemming HC, Wingender J: The biofilm matrix. Nat Rev Microbiol 2010,
8(9):623–633.
2. Costerton JW, Stewart PS, Greenberg EP: Bacterial biofilms: a common
cause of persistent infections. Science 1999, 284(5418):1318–1322.
3. Kuzminski LN: Cranberry juice and urinary tract infections: is there a
beneficial relationship? Nutr Rev 1996, 54(11 Pt 2):S87–S90.
4. Fleet JC: New support for a folk remedy: cranberry juice reduces
bacteriuria and pyuria in elderly women. Nutr Rev 1994, 52(5):168–170.
5. Borukh IF, Kirbaba VI, Senchuk GV: [Antimicrobial properties of cranberry].
Vopr Pitan 1972, 31(5):82.
6. Foo LY, Lu Y, Howell AB, Vorsa N: A-Type proanthocyanidin trimers
from cranberry that inhibit adherence of uropathogenic P-fimbriated
Escherichia coli. J Nat Prod 2000, 63(9):1225–1228.7. Howell AB, Reed JD, Krueger CG, Winterbottom R, Cunningham DG, Leahy
M: A-type cranberry proanthocyanidins and uropathogenic bacterial
anti-adhesion activity. Phytochemistry 2005, 66(18):2281–2291.
8. Bodet C, Piche M, Chandad F, Grenier D: Inhibition of periodontopathogen-
derived proteolytic enzymes by a high-molecular-weight fraction isolated
from cranberry. J Antimicrob Chemother 2006, 57(4):685–690.
9. Hidalgo G, Ponton A, Fatisson J, O’May C, Asadishad B, Schinner T, Tufenkji
N: Induction of a state of iron limitation in uropathogenic Escherichia
coli CFT073 by cranberry-derived proanthocyanidins as revealed by
microarray analysis. Appl Environ Microbiol 2011, 77(4):1532–1535.
10. Ahuja S, Kaack B, Roberts J: Loss of fimbrial adhesion with the addition
of Vaccinum macrocarpon to the growth medium of P-fimbriated
Escherichia coli. J Urol 1998, 159(2):559–562.
11. Sobota AE: Inhibition of bacterial adherence by cranberry juice: potential
use for the treatment of urinary tract infections. J Urol 1984,
131(5):1013–1016.
12. Tapiainen T, Jauhiainen H, Jaakola L, Salo J, Sevander J, Ikaheimo I, Pirttila AM,
Hohtola A, Uhari M: Biofilm formation and virulence of uropathogenic
Escherichia coli in urine after consumption of cranberry-lingonberry juice.
Eur J Clin Microbiol Infect Dis 2012, 31(5):655–662.
13. Yamanaka A, Kimizuka R, Kato T, Okuda K: Inhibitory effects of cranberry
juice on attachment of oral streptococci and biofilm formation. Oral
Microbiol Immunol 2004, 19(3):150–154.
14. Yamanaka A, Kouchi T, Kasai K, Kato T, Ishihara K, Okuda K: Inhibitory effect
of cranberry polyphenol on biofilm formation and cysteine proteases of
Porphyromonas gingivalis. J Periodontal Res 2007, 42(6):589–592.
15. Amer LS, Bishop BM, van Hoek ML: Antimicrobial and antibiofilm activity
of cathelicidins and short, synthetic peptides against Francisella. Biochem
Biophys Res Commun 2010, 396(2):246–251.
16. O’May C, Ciobanu A, Lam H, Tufenkji N: Tannin derived materials can
block swarming motility and enhance biofilm formation in
Pseudomonas aeruginosa. Biofouling 2012, 28(10):1063–1076.
17. Bonifait L, Grenier D: Cranberry polyphenols: potential benefits for dental
caries and periodontal disease. J Can Dent Assoc 2010, 76:a130.
18. Duarte S, Gregoire S, Singh AP, Vorsa N, Schaich K, Bowen WH, Koo H:
Inhibitory effects of cranberry polyphenols on formation and
acidogenicity of Streptococcus mutans biofilms. FEMS Microbiol Lett 2006,
257(1):50–56.
19. Matsushima M, Suzuki T, Masui A, Kasai K, Kouchi T, Takagi A, Shirai T,
Mine T: Growth inhibitory action of cranberry on Helicobacter pylori.
J Gastroenterol Hepatol 2008, 23(Suppl 2):S175–S180.
20. Yamanaka-Okada A, Sato E, Kouchi T, Kimizuka R, Kato T, Okuda K:
Inhibitory effect of cranberry polyphenol on cariogenic bacteria.
Bull Tokyo Dent Coll 2008, 49(3):107–112.
21. La VD, Labrecque J, Grenier D: Cytoprotective effect of proanthocyanidin-rich
cranberry fraction against bacterial cell wall-mediated toxicity in
macrophages and epithelial cells. Phytother Res 2009, 23(10):1449–1452.
22. Toivanen M, Ryynanen A, Huttunen S, Duricova J, Riihinen K, Torronen R,
Lapinjoki S, Tikkanen-Kaukanen C: Binding of Neisseria meningitidis pili to
berry polyphenolic fractions. J Agric Food Chem 2009, 57(8):3120–3127.
23. Pseudomonas aeruginosa: Infections and Treatment, Volume 12. New York:
Informa Health Care; 1994.
24. Ciofu O, Hansen CR, Hoiby N: Respiratory bacterial infections in cystic
fibrosis. Curr Opin Pulm Med 2013, 19(3):251–258.
25. Dean SN, Bishop BM, van Hoek ML: Susceptibility of pseudomonas
aeruginosa biofilm to alpha-helical peptides: D-enantiomer of LL-37.
Front Microbiol 2011, 2:128.
26. Tremblay J, Deziel E: Improving the reproducibility of Pseudomonas
aeruginosa swarming motility assays. J Basic Microbiol 2008, 48(6):509–515.
27. Durham-Colleran MW, Verhoeven AB, van Hoek ML: Francisella novicida
forms in vitro biofilms mediated by an orphan response regulator.
Microb Ecol 2010, 59(3):457–465.
28. Dean SN, Bishop BM, van Hoek ML: Natural and synthetic cathelicidin
peptides with anti-microbial and anti-biofilm activity against Staphylococcus
aureus. BMC Microbiol 2011, 11:114.
29. O’Toole GA: Microtiter dish biofilm formation assay. J Visual Exp 2011, 47:2437.
30. Ahmad S, Hunter L, Qin A, Mann BJ, van Hoek ML: Azithromycin effectiveness
against intracellular infections of Francisella. BMC Microbiol 2010, 10:123.
31. Hall MJ, Middleton RF, Westmacott D: The fractional inhibitory concentration
(FIC) index as a measure of synergy. J Antimicrob Chemother 1983,
11(5):427–433.
Ulrey et al. BMC Complementary and Alternative Medicine 2014, 14:499 Page 12 of 12
http://www.biomedcentral.com/1472-6882/14/49932. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D,
Chamberland S, Renau T, Leger R, Hecker S, Watkins W, Hoshino K, Ishida H,
Lee VJ: Identification and characterization of inhibitors of multidrug
resistance efflux pumps in Pseudomonas aeruginosa: novel agents for
combination therapy. Antimicrob Agents Chemother 2001, 45(1):105–116.
33. Tolker-Nielsen T, Sternberg C: Growing and Analyzing Biofilms in Flow
Chambers. In Current Protocols in Microbiology. Hoboken, NJ: John Wiley &
Sons, Inc; 2005.
34. Zhou W, Capello M, Fredolini C, Racanicchi L, Piemonti L, Liotta LA, Novelli
F, Petricoin EF: Proteomic analysis reveals Warburg effect and anomalous
metabolism of glutamine in pancreatic cancer cells. J Proteome Res 2012,
11(2):554–563.
35. Elias JE, Gygi SP: Target-decoy search strategy for increased confidence in
large-scale protein identifications by mass spectrometry. Nat Methods
2007, 4(3):207–214.
36. McKenney ES, Sargent M, Khan H, Uh E, Jackson ER, San Jose G, Couch RD,
Dowd CS, van Hoek ML: Lipophilic prodrugs of FR900098 are antimicrobial
against Francisella novicida in vivo and in vitro and show GlpT independent
efficacy. PLoS One 2012, 7(10):e38167.
37. O’Loughlin CT, Miller LC, Siryaporn A, Drescher K, Semmelhack MF, Bassler BL:
A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and
biofilm formation. Proc Natl Acad Sci U S A 2013, 110(44):17981–17986.
38. Wu H, Song Z, Hentzer M, Andersen JB, Molin S, Givskov M, Hoiby N:
Synthetic furanones inhibit quorum-sensing and enhance bacterial
clearance in Pseudomonas aeruginosa lung infection in mice.
J Antimicrob Chemother 2004, 53(6):1054–1061.
39. Lin B, Johnson BJ, Rubin RA, Malanoski AP, Ligler FS: Iron chelation by
cranberry juice and its impact on Escherichia coli growth. BioFactors
(Oxford, England) 2011, 37(2):121–130.
40. Andres MT, Viejo-Diaz M, Perez F, Fierro JF: Antibiotic tolerance induced
by lactoferrin in clinical Pseudomonas aeruginosa isolates from cystic
fibrosis patients. Antimicrob Agents Chemother 2005, 49(4):1613–1616.
41. Woolfrey BF, Lally RT, Ederer MN, Quall CO: Evaluation of the automicrobic
system for susceptibility testing of Pseudomonas aeruginosa to
gentamicin, tobramycin, and amikacin. J Clin Microbiol 1984, 19(4):502–505.
42. Koo H, Duarte S, Murata RM, Scott-Anne K, Gregoire S, Watson GE, Singh AP,
Vorsa N: Influence of cranberry proanthocyanidins on formation of
biofilms by Streptococcus mutans on saliva-coated apatitic surface
and on dental caries development in vivo. Caries Res 2010, 44(2):116–126.
43. Leshem R, Maharshak I, Ben Jacob E, Ofek I, Kremer I: The effect of
nondialyzable material (NDM) cranberry extract on formation of contact
lens biofilm by Staphylococcus epidermidis. Invest Ophthalmol Vis Sci
2011, 52(7):4929–4934.
44. Feldman M, Weiss EI, Ofek I, Steinberg D: Interference of cranberry
constituents in cell-cell signaling system of Vibrio harveyi. Curr Microbiol
2009, 59(4):469–474.
45. Labrecque J, Bodet C, Chandad F, Grenier D: Effects of a high-molecular-
weight cranberry fraction on growth, biofilm formation and adherence
of Porphyromonas gingivalis. J Antimicrob Chemother 2006, 58(2):439–443.
46. Polak D, Naddaf R, Shapira L, Weiss EI, Houri-Haddad Y: Protective potential
of non-dialyzable material fraction of cranberry juice on the virulence
of P. gingivalis and F. nucleatum mixed infection. J Periodontol 2013,
84(7):1019–1025.
47. O’May C, Tufenkji N: The swarming motility of Pseudomonas aeruginosa
is blocked by cranberry proanthocyanidins and other tannin-containing
materials. Appl Environ Microbiol 2011, 77(9):3061–3067.
48. Foo LY, Lu Y, Howell AB, Vorsa N: The structure of cranberry proanthocyanidins
which inhibit adherence of uropathogenic P-fimbriated Escherichia coli
in vitro. Phytochemistry 2000, 54(2):173–181.
49. Cai Y, Wang R, An MM, Liang BB: Iron-Depletion prevents biofilm formation
in Pseudomonas Aeruginosa through twitching mobility and quorum
sensing. Brazilian J Microbiol 2010, 41(1):37–41.
50. Farha MA, Brown ED: Discovery of antibiotic adjuvants. Nat Biotechnol
2013, 31(2):120–122.
doi:10.1186/1472-6882-14-499
Cite this article as: Ulrey et al.: Cranberry proanthocyanidins have
anti-biofilm properties against Pseudomonas aeruginosa. BMC
Complementary and Alternative Medicine 2014 14:499.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
